Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020414 | 0.80 | CYP19A1 (0.46) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL4478797 | 0.80 | CYP19A1 (0.46) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL13108584 | 0.80 | CYP19A1 (0.46) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL2401004 | 0.80 | CYP19A1 (0.46) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL23873114 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL8902099 | 0.78 | CYP19A1 (0.45) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL11898438 | 0.77 | CYP19A1 (0.44) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL15777948 | 0.77 | CYP19A1 (0.44) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL13925693 | 0.76 | CYP19A1 (0.43) | CYP19A1FOLH1CYP1A1 | |
| SCHEMBL18900633 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| CN-100430060-C | Pharmaceutical use of indolinone in combination with a chemotherapeutic agent for cell proliferative disorders | SUGEN INC (US) | 2008-11-05 | — | — | CN | disclosed |
| CN-101259131-A | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN INC (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1562600-A4 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN INC (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1446117-A4 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN INC (US) | 2008-01-23 | — | — | EP | disclosed |
| CN-101052394-A | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN INC (US) | 2007-10-10 | — | — | CN | disclosed |
| CN-100338059-C | 3-(4-amidopyrrol-2-2ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN CO LTD (US) | 2007-09-19 | — | — | CN | disclosed |
| US-7256189-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1446117-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | Sugen, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | SUGEN, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004045523-A2 | COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS | SUGEN, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1370554-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | SUGEN, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035009-A2 | TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS | SUGEN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002066463-A1 | 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K3, CDK2 | CYP19A1 2734/4885FOLH1 3498/4885CYP1A1 3830/4885 |
| US-20040152759-A1 | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | MKI67, CCNA1, CCNI | CYP19A1 141/4885FOLH1 2269/4885CYP1A1 778/4885 |
| US-20040102510-A1 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | MAP3K15, MAP3K19, MAP3K9 | CYP19A1 4208/4885FOLH1 3642/4885CYP1A1 4223/4885 |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | CYP19A1 1035/4885FOLH1 715/4885CYP1A1 981/4885 |
| US-20030092917-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors | PDPK1, MKNK1, PKN2 | CYP19A1 4584/4885FOLH1 3024/4885CYP1A1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.